CD274 and lung adenocarcinoma: KRAS-mutant lung adenocarcinomas associated with KEAP1 mutational inactivation demonstrated lower expression rates of PD-L1 and other immune markers, proving refractory to anti–PD-1 antibody therapy [51,52].